4.7 Article

MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD)

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 133, Issue 5, Pages 1286-1293

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2012.400

Keywords

-

Categories

Funding

  1. NIAMS [R01AR26427-18]
  2. Veterans Administration merit grant from the Department of Veterans Affairs (Veterans Health Administration
  3. Office of Research and Development, Biomedical Laboratory Research and Development)
  4. NIH [5T32AR007411-29, P30 CA 046934]
  5. Southwestern Skin Cancer SPORE Pilot project
  6. Intramural Research Program of the NIH, National Cancer Institute for Cancer Research
  7. Bifeng Gao at the University of Colorado Microarray Core

Ask authors/readers for more resources

Melanoma is an aggressive cancer that metastasizes rapidly and is refractory to conventional chemotherapies. Identifying microRNAs (miRNAs) that are responsible for this pathogenesis is therefore a promising means of developing new therapies. We identified miR-26a through microarray and quantitative reverse-transcription PCR (qRT-PCR) experiments as an miRNA that is strongly downregulated in melanoma cell lines as compared with primary melanocytes. Treatment of cell lines with miR-26a mimic caused significant and rapid cell death compared with a negative control in most melanoma cell lines tested. In surveying targets of miR-26a, we found that protein levels of SMAD1 (mothers against decapentaplegic homolog 1) and BAG-4/SODD were strongly decreased in sensitive cells treated with miR-26a mimic as compared with the control. The luciferase reporter assays further demonstrated that miR-26a can repress gene expression through the binding site in the 3' untranslated region (3'UTR) of SODD (silencer of death domains). Knockdown of these proteins with small interfering RNA (siRNA) showed that SODD has an important role in protecting melanoma cells from apoptosis in most cell lines sensitive to miR-26a, whereas SMAD1 may have a minor role. Furthermore, transfecting cells with a miR-26a inhibitor increased SODD expression. Our findings indicate that miR-26a replacement is a potential therapeutic strategy for metastatic melanoma, and that SODD, in particular, is a potentially useful therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available